ARMP Stock Forecast: Armata Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$3.01
−5.05% on the day

The median 12-month analyst price target for Armata Pharmaceuticals, Inc. is $18. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 86 of 100 as at 18 Nov 2026 — inside the top quartile.

Market cap
$98.9M
Ticker Nerd rank
86/ 100
Median analyst target
$18
Analysts covering
2
Revenue$0.0
Operating income−$8.8M
Net income−$115.3M
Free cash flow−$5.8M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−19.1%
1M
−2.0%
YTD
−52.1%
1Y
−58.8%
From 52W high
−79.7%
From 52W low
+13.2%
$3
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Armata Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
86/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
97
Revisions
93
Value
88
Momentum
61
Volatility
57
Quality
52
Growth
40
Issuance
15

Accruals (97): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ARMP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARMP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26ARMPHigh $20Median $18Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$15
Low
$18
Median
$20
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Sept 2026HC Wainwright & Co.ReiteratesBuy—
23 Feb 2026HC Wainwright & Co.MaintainsBuy—
5 Jan 2026Jones TradingInitiatesBuy—
19 May 2025HC Wainwright & Co.MaintainsBuy—
19 Dec 2024HC Wainwright & Co.ReiteratesBuy—
14 Nov 2024HC Wainwright & Co.ReiteratesBuy—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024HC Wainwright & Co.ReiteratesBuy—
11 July 2024HC Wainwright & Co.ReiteratesBuy—
8 May 2024HC Wainwright & Co.ReiteratesBuy—
22 Mar 2024HC Wainwright & Co.MaintainsBuy—
14 Aug 2023HC Wainwright & Co.ReiteratesBuy—
12 May 2023HC Wainwright & Co.ReiteratesBuy—
17 Mar 2023HC Wainwright & Co.ReiteratesBuy—
7 Mar 2023HC Wainwright & Co.ReiteratesBuy—
22 Mar 2021HC Wainwright & Co.MaintainsBuy—
15 May 2020H.C. WainwrightReiteratesBuy—
15 May 2020HC Wainwright & Co.ReiteratesBuy—
20 Mar 2020H.C. WainwrightReiteratesBuy—
20 Mar 2020HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ARMP.

Market Radar

This page is one stock. Monday covers all of them.

ARMP appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ARMP vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Armata Pharmaceuticals, Inc. returned −58.8% against +9.2% for the S&P 500, dividends included.

ARMP vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26ARMPS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARMP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
13.1×

Cheaper than 10% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
173.6%

Higher than 95% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−25.1%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Armata Pharmaceuticals, Inc. has a market value of $98.9M and an enterprise value of $332.2M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$282.6M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$24.5M, after $506K of capital spending.

  • Shares outstanding: 37.2M.

  • Armata Pharmaceuticals, Inc. employs 61 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

ARMP and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARMPArmata Pharmaceuticals, Inc.$98.9M86
RTSNRetension Pharmaceuticals, Inc.$115.7M1
SPRBSpruce Biosciences, Inc.$117.4M10
UPBUpstream Bio, Inc.$113.9M20
OKUROnKure Therapeutics, Inc.$113.9M52
IMUXImmunic, Inc.$119.4M19
NTHINeOnc Technologies Holdings, Inc.$119.8M31

Take a look at ARMP’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Armata Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ARMP

What is the ARMP stock price forecast for 2026-2027?

The median 12-month analyst price target for Armata Pharmaceuticals, Inc. is $18, with estimates ranging from $15 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARMP stock a buy right now?

Of the 2 analysts covering Armata Pharmaceuticals, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Armata Pharmaceuticals, Inc. 86 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARMP?

As at 18 Nov 2026, Armata Pharmaceuticals, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (97 of 100).

Will ARMP stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $18, and Ticker Nerd's factor model ranks Armata Pharmaceuticals, Inc. 86 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARMP stock forecast for 2030?

No analyst covering Armata Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $20 over the next 12 months.

How has ARMP stock performed over the past year?

Armata Pharmaceuticals, Inc. returned -58.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Armata Pharmaceuticals, Inc. do?

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on phage-based medicines designed to target specific bacterial pathogens, with programs addressing infections such as Staphylococcus aureus bacteremia and Pseudomonas aeruginosa-related disease.

Company

About Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. The company’s current work centers on phage-based medicines designed to target specific bacterial pathogens, with programs addressing infections such as Staphylococcus aureus bacteremia and Pseudomonas aeruginosa-related disease. Its platform combines natural and synthetic bacteriophages with proprietary engineering, microbiological surveillance, and drug development capabilities to support product design, manufacturing, and clinical testing. Armata Pharmaceuticals operates as a specialist in infectious disease therapeutics, serving an important role in the broader biopharmaceutical market by advancing alternative approaches to conventional antibiotics.

CEO Dr. Deborah L. Birx M.D. · 61 employees · United States · https://www.armatapharma.com